Streptococcus pneumonia

At IBT Bioservices, we understand the critical need for effective interventions against Streptococcus pneumonia infections. We specialize in comprehensive preclinical testing services aimed at assessing the safety and efficacy of potential treatments and vaccines against this versatile and virulent species of bacterium.

Diseases

Pneumonia, Bacteremia, and meningitis

Infects

Elderly, young children, and immunocompromised humans

Symptoms

Fever, cough, chills, shortness of breath, chest pain, and in some cases, mental confusion, disorientation.

Bacterial Characteristics

Streptococcus pneumonia is a gram-positive facultative anaerobic bacterium. The diseases caused by Strep pneumonia contribute to a public health problem worldwide, affecting both developed and underdeveloped countries. It is crucial to continue researching and developing protective and therapeutic interventions.

Streptococcus pneumonia is a significant pathogen responsible for causing severe infections, including bloodstream infections, pneumonia, and meningitis. This bacterium has several virulence factors, such as pneumolysin, adhesins, biofilm formation and antibiotic resistance, that can make it challenging to treat, making it crucial to develop novel therapies to combat these infections.

At IBT, our expert team of scientists has deep expertise in the biology of S. pneumonia. It utilizes state-of-the-art facilities and advanced methodologies to perform thorough preclinical in vitro and in vivo testing for Streptococcus pneumonia.

Our Models Help Investigators

Target Virulence Factors

Understand Pathogenesis

Reduce Disease Burden

Contact us today to learn more about how our preclinical testing services can accelerate the development of promising treatments and vaccines for Streptococcus pneumonia.

Our preclinical testing services for Streptococcus pneumonia encompasses:

In Vitro Assays

Using advanced molecular and cellular techniques, we evaluate the efficacy of potential drugs and vaccines against Streptococcus pneumonia. These studies help identify compounds that can effectively inhibit bacterial growth, disrupt virulence factors, enhance host immune response or review mechanism of actions. We help clients assess their therapeutic candidates and investigate the mechanisms of action of potential interventions, providing valuable insights into their ability to combat Streptococcus pneumonia infections. IBT can offer a variety of assays to support your research, for example, ELISA, Luminex, flow cytometry and toxin-based viability assays.

At IBT, we are dedicated to advancing the field of Streptococcus pneumonia research and development through reliable and accurate in vitro and in vivo preclinical testing services. Our commitment to scientific excellence, ethical practices, and adherence to regulatory guidelines positions us as a trusted partner in the fight against this bacterial infection. We provide you with high quality data and documentation supporting your regulatory filings.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

REAGENTS

IN-VITRO Services

ANIMAL SERVICES

By Diseases Target